Gaetano Sodaro

Paris, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

ZNF224 enhances the oncogenic function of p21 via p53 and AKT pathways in melanoma.

ZNF224 enhances the oncogenic function of p21 via p53 and AKT pathways in melanoma.

Journal: The FEBS journal

Published: April 24, 2024

A multiparametric niche-like drug screening platform in acute myeloid leukemia.

A multiparametric niche-like drug screening platform in acute myeloid leukemia.

Journal: Blood cancer journal

Published: November 30, 2021

Cystine uptake inhibition potentiates front-line therapies in acute myeloid leukemia.

Cystine uptake inhibition potentiates front-line therapies in acute myeloid leukemia.

Journal: Leukemia

Published: October 12, 2021

P2RY2-AKT activation is a therapeutically actionable consequence of XPO1 inhibition in acute myeloid leukemia.

P2RY2-AKT activation is a therapeutically actionable consequence of XPO1 inhibition in acute myeloid leukemia.

Journal: Nature cancer

Published: July 18, 2021

Targeting acute myeloid leukemia dependency on VCP-mediated DNA repair through a selective second-generation small-molecule inhibitor.

Targeting acute myeloid leukemia dependency on VCP-mediated DNA repair through a selective second-generation small-molecule inhibitor.

Journal: Science translational medicine

Published: December 12, 2020

The Folate Cycle Enzyme MTHFR Is a Critical Regulator of Cell Response to MYC-Targeting Therapies.

The Folate Cycle Enzyme MTHFR Is a Critical Regulator of Cell Response to MYC-Targeting Therapies.

Journal: Cancer discovery

Published: August 18, 2019

ZNF224 is a transcriptional repressor of AXL in chronic myeloid leukemia cells.

ZNF224 is a transcriptional repressor of AXL in chronic myeloid leukemia cells.

Journal: Biochimie

Published: June 18, 2018

Role of ZNF224 in c-Myc repression and imatinib responsiveness in chronic myeloid leukemia.

Role of ZNF224 in c-Myc repression and imatinib responsiveness in chronic myeloid leukemia.

Journal: Oncotarget

Published: July 26, 2017

The Complex Role of the ZNF224 Transcription Factor in Cancer.

The Complex Role of the ZNF224 Transcription Factor in Cancer.

Journal: Advances in protein chemistry and structural biology

Published: February 21, 2017

Role of ZNF224 in cell growth and chemoresistance of chronic lymphocitic leukemia.

Role of ZNF224 in cell growth and chemoresistance of chronic lymphocitic leukemia.

Journal: Human molecular genetics

Published: October 21, 2016

The hematopoietic tumor suppressor interferon regulatory factor 8 (IRF8) is upregulated by the antimetabolite cytarabine in leukemic cells involving the zinc finger protein ZNF224, acting as a cofactor of the Wilms' tumor gene 1 (WT1) protein.

The hematopoietic tumor suppressor interferon regulatory factor 8 (IRF8) is upregulated by the antimetabolite cytarabine in leukemic cells involving the zinc finger protein ZNF224, acting as a cofactor of the Wilms' tumor gene 1 (WT1) protein.

Journal: Leukemia research

Published: July 06, 2015

WT1-mediated repression of the proapoptotic transcription factor ZNF224 is triggered by the BCR-ABL oncogene.

WT1-mediated repression of the proapoptotic transcription factor ZNF224 is triggered by the BCR-ABL oncogene.

Journal: Oncotarget

Published: March 23, 2015

Showing 1-12 of 12

Last Updated: 09/26/2026